Corvus Pharmaceuticals, Inc. (CRVS) vs Kura Oncology, Inc. (KURA)

Corvus Pharmaceuticals, Inc. and Kura Oncology, Inc. are both Biotechnology companies. Corvus Pharmaceuticals, Inc. and Kura Oncology, Inc. are of similar size ($992.6M and $977.7M). Corvus Pharmaceuticals, Inc. has the higher net margin (0.00% vs −384.3%) and the lower return on invested capital (−352.5% vs 0.00%). Across the 14 metrics below, Corvus Pharmaceuticals, Inc. leads on 12 and Kura Oncology, Inc. on 2.

Valuation

Metric CRVS KURA Biotechnology median
P/E n/m n/m 7.88
P/S n/m 12.45 11.47
P/B 4.76 19.85 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 5.86 10.73
Earnings yield (5.25%) (31.15%) (28.84%)
Free cash flow yield (4.21%) (12.21%) (23.03%)

Profitability

Metric CRVS KURA Biotechnology median
Gross margin 0.00% 99.35% 65.16%
Operating margin 0.00% (411.90%) 0.00%
Net margin 0.00% (384.30%) 0.00%
Free cash flow margin 0.00% (152.06%) 0.00%
Return on equity (18.98%) (167.71%) (57.72%)
Return on assets (17.64%) (46.73%) (49.22%)
Return on invested capital (352.49%) 0.00% 0.00%

Growth

Metric CRVS KURA Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 81.21% (57.43%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRVS KURA Biotechnology median
Debt to equity 0.00 0.20 0.00
Current ratio 16.16 4.73 4.73
Net debt to EBITDA 1.28 2.11 0.96

Dividend

Metric CRVS KURA Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRVS KURA Biotechnology median
Market cap 992.63m 977.67m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack